Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Tasosartan. |
| Canagliflozin | The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Tasosartan. |
| Drospirenone | The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Drospirenone. |
| Eplerenone | The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tasosartan. |
| Semuloparin | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Tasosartan. |
| Methyclothiazide | Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Bendroflumethiazide | Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Benzthiazide | Benzthiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Cyclothiazide | Cyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Hydroflumethiazide | Hydroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Chlorothiazide | Chlorothiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Hydrochlorothiazide | Hydrochlorothiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Trichlormethiazide | Trichlormethiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Polythiazide | Polythiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Mebutizide | Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Cyclopenthiazide | Cyclopenthiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Buthiazide | Buthiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Lithium citrate | The serum concentration of Lithium citrate can be increased when it is combined with Tasosartan. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be increased when it is combined with Tasosartan. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be increased when it is combined with Tasosartan. |
| Tolvaptan | The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Tasosartan. |
| Trimethoprim | The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tasosartan. |
| Ciprofloxacin | The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Ciprofloxacin. |
| Cyclosporine | The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Cyclosporine. |
| Nicorandil | The risk or severity of hyperkalemia can be increased when Nicorandil is combined with Tasosartan. |
| Icosapent | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Icosapent. |
| Mesalazine | The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Tasosartan. |
| Indomethacin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Indomethacin. |
| Nabumetone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Nabumetone. |
| Tenoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Tenoxicam. |
| Celecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Celecoxib. |
| Tolmetin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Tolmetin. |
| Rofecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Rofecoxib. |
| Piroxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Piroxicam. |
| Fenoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Fenoprofen. |
| Valdecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Valdecoxib. |
| Diclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Diclofenac. |
| Sulindac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Sulindac. |
| Flurbiprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Flurbiprofen. |
| Etodolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Etodolac. |
| Mefenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Mefenamic acid. |
| Naproxen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Naproxen. |
| Sulfasalazine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Sulfasalazine. |
| Phenylbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Phenylbutazone. |
| Meloxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Meloxicam. |
| Carprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Carprofen. |
| Diflunisal | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Diflunisal. |
| Salicylic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Salicylic acid. |
| Meclofenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Meclofenamic acid. |
| Acetylsalicylic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Acetylsalicylic acid. |
| Oxaprozin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Oxaprozin. |
| Ketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Ketoprofen. |
| Balsalazide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Balsalazide. |
| Ibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Ibuprofen. |
| Lumiracoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Lumiracoxib. |
| Magnesium salicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Magnesium salicylate. |
| Salsalate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Salsalate. |
| Choline magnesium trisalicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Choline magnesium trisalicylate. |
| Antrafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Antrafenine. |
| Aminophenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Aminophenazone. |
| Antipyrine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Antipyrine. |
| Tiaprofenic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Tiaprofenic acid. |
| Etoricoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Etoricoxib. |
| Taxifolin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Taxifolin. |
| Oxyphenbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Oxyphenbutazone. |
| Licofelone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Licofelone. |
| Nimesulide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Nimesulide. |
| Benoxaprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Benoxaprofen. |
| Metamizole | The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Metamizole. |
| Zomepirac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Zomepirac. |
| Cimicoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Cimicoxib. |
| Lornoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Lornoxicam. |
| Aceclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Aceclofenac. |
| Zaltoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Zaltoprofen. |
| Azapropazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Azapropazone. |
| Parecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Parecoxib. |
| Salicylamide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Salicylamide. |
| Kebuzone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Kebuzone. |
| Isoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Isoxicam. |
| Indoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Indoprofen. |
| Ibuproxam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Ibuproxam. |
| Floctafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Floctafenine. |
| Fenbufen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Fenbufen. |
| Etofenamate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Etofenamate. |
| Epirizole | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Epirizole. |
| Benzydamine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Benzydamine. |
| Dexibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Dexibuprofen. |
| Dexketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Dexketoprofen. |
| Droxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Droxicam. |
| Tolfenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Tolfenamic acid. |
| Firocoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Firocoxib. |
| Clonixin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Clonixin. |
| Morniflumate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Morniflumate. |
| Propacetamol | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Propacetamol. |
| Talniflumate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Talniflumate. |
| Robenacoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Robenacoxib. |
| Tepoxalin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Tepoxalin. |
| Flunixin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Flunixin. |
| Polmacoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Polmacoxib. |
| Nitroaspirin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Nitroaspirin. |